• L Fananapazir and D McAreavey.
• Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892-1650 USA. fananapA@gwgate.nhlbi.nih.gov
• Pacing Clin Electrophysiol. 1997 Feb 1; 20 (2 Pt 2): 478-501.

AbstractHypertrophic cardiomyopathy (HCM) is a heritable disease characterized by LV hypertrophy with markedly variable clinical, morphological, and genetic manifestations. It is the most common cause of sudden death in otherwise healthy young individuals. HCM patients often have disabling symptoms and are prone to arrhythmias. Frequently, there is associated LV systolic and diastolic dysfunction, LV outflow obstruction, and myocardial ischemia. Over the past decade, progress has been made in identifying patients who are at high risk for sudden death, in elucidating potential mechanisms of sudden death, and in defining therapeutic algorithms that may improve prognosis. It has also been possible to determine the genetic defect in some of the patients and to correlate clinical findings with the molecular defects. An exciting development has been the use of dual chamber pacemaker as an alternative to cardiac surgery to improve symptoms and relieve LV outflow obstruction.

23 keywords...

hide…